New Double Mutant Coronavirus Discovered in San Francisco 1CARE Medical Diagnostics partners with specimen collection units and healthcare facilities to protect California
In seeking COVID-19 testing, our partners may choose SalivaDirect as a non-invasive and more affordable option. This test is developed with mass testing and observation in mind.
Interested submitting samples?
Every School Safe and Open is a set of playbooks of SalivaDirect, a partner of 1CARE Diagnostics in providing high-quality COVID-19 testing.
The four playbooks cover topics ranging from Federal Funding, Mitigation, Detection And Vaccination.
SalivaDirect™, a new non-invasive approach to testing possible COVID-19 cases, was developed at the Yale School of Public Health. This process is highly recommended for large-scale testing and offers several benefits, when compared to traditional testing processes.
The test relies on rt-PCR technology, like any other rt-PCR-based COVID test. The difference is that a saliva sample (spit) is collected, which is then extracted for the RNA component of the virus. The extracted sample is then put through the PCR process to obtain the final result of the sample—positive or negative for the SARS-Covid-19 virus. The sensitivity and efficiency of this test is similar to nasal sample-based methods.
The stability of the saliva sample is significantly better than the nasal sample, however, eliminating the need for expensive collection equipment.
SalivaDirect, a new approach at testing possible COVID-19 cases, was developed at the Yale School of Public Health. This process is highly recommended to be used for large-scale testing and offers several benefits compared to traditional testing processes.
The Yale School of Public Health has approved 1CARE Diagnostics as a testing laboratory to perform COVID-19 saliva testing.
SalivaDirect™ is less invasive, less painful, and more affordable. Moreover, unlike a nasopharyngeal (NP) swab, it requires only a small saliva sample. With the supervision of a healthcare professional, it lets an individual collect his or her own saliva sample, completely without the need for swabs or other collection tools.
SalivaDirect™ takes less than a minute to conduct, a fast process for individuals and a safe one for the healthcare professionals, whose risks of being exposed to COVID-19 will be reduced. More importantly, SalivaDirect is highly accurate—it produces a 94% success rate, compared to an NP test.
A saliva-based approach at detecting COVID-19 is easier to facilitate and probe.
The FDA also granted SalivaDirect with an emergency use authorization (EUA).
What does it mean? Going back to our normal lives will happen sooner than we think.